Loading...
For patients undergoing total hip or knee replacement, aspirin has become the most widely prescribed agent for preventing venous thromboembolism (VTE) after surgery. Evidence from both observational and randomized studies supported this trend, but some uncertainty persisted about the relative effectiveness and safety of aspirin compared with anticoagulants. Thus, researchers launched the randomized PEPPER trial in the United States and Canada in 2016; it involved ≈7000 patients undergoing hip arthroplasty and ≈8000 undergoing knee arthroplasty.
Patients received aspirin (81 mg twice daily), warfarin (target international normalized ratio, 2.0), or rivaroxaban (10 mg daily) for 30 days. Six-month outcomes were assessed.
The i…